Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

IRONDisc Medicine, IncSigning up patients

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Myelofibrosis; Anemia · Anemia · Myelofibrosis · Myelofibrosis Due to and Following Polycythemia Vera · Primary Myelofibrosis · Post-essential Thrombocythemia Myelofibrosis · Myelodysplastic Syndromes

0Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

No warning signs right now. That's why the score is 0.

Score over time

Stage
Phase 1/2
Patients
150 (planned)
Started
Jun 6, 2022
Main results expected
May 2027
Fully finished
Jun 2027
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Safety and Tolerability of DISC-0974 (Phase 1b only)

    Measured over: From Day 1 to the end of treatment on Day 169

  • Safety and Tolerability of DISC-0974 (Phase 1b only)

    Measured over: From Day 1 to the end of treatment on Day 169

  • Safety and Tolerability of DISC-0974 (Phase 1b only)

    Measured over: From Day 1 to the end of treatment on Day 169

  • Safety and Tolerability of DISC-0974 (Phase 1b only)

    Measured over: From Day 1 to the end of treatment on Day 169

  • Safety and Tolerability of DISC-0974 assessed through blood testing (Phase 1b only)

    Measured over: From Day 1 to the end of treatment on Day 169

  • Safety and Tolerability of DISC-0974 assessed through urine testing (Phase 1b only)

    Measured over: From Day 1 to the end of treatment on Day 169

  • Transfusion-dependent (TD) high cohort: transfusion independence (Phase 2 only)

    Measured over: From Day 1 to the end of treatment on Day 169

  • TD low cohort: transfusion independence (Phase 2 only)

    Measured over: From Day 1 to the end of treatment on Day 169

  • Non-transfusion-dependent (nTD) cohort: anemia response (Phase 2 only)

    Measured over: From Day 1 to the end of treatment on Day 169

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • none

Raw record changes

  • none yet

Trial ID NCT05320198 · record last updated 2026-10-22 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT05320198) ↗